SCHEMBL1713306

SCHEMBL1713306

CC(C)NC=N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16091133 0.76 ADH1B (0.33)
SCHEMBL24074932 0.72
SCHEMBL17323920 0.67
SCHEMBL25133181 0.67
SCHEMBL14111097 0.67 ADH1B (0.50)
SCHEMBL4968122 0.67 ADH1B (0.50)
SCHEMBL4968115 0.67 ADH1B (0.50)
SCHEMBL23950985 0.65
SCHEMBL18659592 0.65
SCHEMBL4969067 0.64 ADH1B (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227859-A1 TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH LLC 2010-09-09 US claimed
EP-2144893-A2 TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2010-01-20 EP claimed
WO-2008137816-A2 TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH (US) 2008-11-13 WO claimed
WO-2023081893-A1 INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES ENTRADA THERAPEUTICS, INC. (US) 2023-05-11 WO disclosed
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-02 US disclosed
US-11535643-B2 Macrolides with modified desosamine sugars and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-12-27 US disclosed
CN-107141293-B Nitrogen-containing heterocyclic compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2022-09-23 CN disclosed
CN-115057861-A Nitrogen-containing heterocyclic compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2022-09-16 CN disclosed
US-20220205009-A1 MUTATED tRNA FOR CODON EXPANSION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-06-30 US disclosed
CN-114096531-A THR-beta modulators and methods of use thereof 阿利戈斯治疗公司 2022-02-25 CN disclosed
US-11008358-B2 Synthesis of desosamines PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-05-18 US disclosed
CN-101198613-A Substituted tetrahydroquinolines MERCK PATENT GMBH (DE) 2008-06-11 CN disclosed
EP-1927590-A1 METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND Ube Industries, Ltd. (JP) 2008-06-04 EP disclosed
CN-1878556-A Combinations of drugs for the treatment of neoplasms COMBINATORX INC (US) 2006-12-13 CN disclosed
US-5264448-A Thioamides, oxazole ring, insecticides, miticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-11-23 US disclosed
EP-0394043-A1 An amide compound and its production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-10-24 EP disclosed
US-4335043-A Substituted N-methylene derivatives of thienamycin MERCK & CO., INC. (US) 1982-06-15 US disclosed
US-4232030-A ANTIBIOTICS MERCK & CO., INC. (US) 1980-11-04 US disclosed
US-4194047-A Substituted N-methylene derivatives of thienamycin MERCK & CO., INC. (US) 1980-03-18 US disclosed
EP-0001264-A1 Substituted N-methylene derivatives of thienamycin sulfoxide and sulfone and their preparation MERCK & CO. INC. (US) 1979-04-04 EP disclosed